Investigators Dialogue 2019 – Thank You Investigators!

KUALA LUMPUR, 25 April 2019 – We had the CRM Investigator Dialogue 2019, a platform to discuss relevant matters in conducting Sponsored Research.

We invited Ms Yam Pei Ching (NPRA), Dr Hjh Salina Abdul Aziz (MREC), Dr Hjh Rosaida Hj Md Said (Investigator, Hospital Ampang) and Ms SuLyn Yip (Novotech) to give a talk and updates on their respective areas.

Special thanks to Dato’ Dr Goh Pik Pin, Director of Clinical Research Centre Malaysia for her welcoming speech.

Last but not least, a big thank you to all investigators for your time and thoughts given for this year Investigator Dialogue.


Thank You! – Industry Dialogue 2019/1

Its the first CRM Industry Dialogue for 2019!

CRM Industry Dialogue provides an avenue for Pharmaceutical companies (sponsors) and CROs to directly convey any issues, suggestions or opinions that they may have to CRM. Besides strengthening cooperation and networking between all parties, CRM also takes the opportunity to update the clinical research industry on local laws, guidelines and regulations. By bringing together these industry players, CRM uses this platform to connect with them and provide upates on its current and future activities.

Guest Speakers
We would to thank our guest speakers Ms. Yip Su Lyn (Country Manager, Novotech), Dr. Zaril Harza bin Zakaria (Deputy Director, Centre for Investigational New Product, NPRA) and Dr. Hjh Salina Abdul Aziz (Chairperson, MREC) for sharing important updates with us today.

Dialogue Session
We invited Dr Hjh Salina Abd Aziz (Chairperson, MREC), Dr Zaril Harza Zakari (Deputy Director, NPRA), Puan Aidahwaty (Director Technical Evaluation, MDA), Mr Lau Thye Mun (Deputy Director, Royal Malaysian Customs Department) and Mr Ewe Kheng Huat (Executive Director, PhAMA) to have a dialogue session with the industry players.

Our humble gratitude to all.


Congratulations Free Paper Presentation Winners at the NHAM-CRM Research Track 2019!

Congratulations to the Free Paper Presentation winners at the recent NHAM-CRM Research Track 2019!

Biomedical/Public Health/Clinical category:

Winner: Ms Nor Firdous Mohamed (Universiti Pendidikan Sultan Idris)
Title: “Development and Validation of a Coronary Heart Diseases Specific-Complementary Alternative Medicines Usage Questionnaire

1st Runner Up: Dr Hanis Hidayu Kasim (Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia)
Title: “Is ABPM a Better Device for Monitoring Pregnancy than Sphygmomanometer?

2nd Runner Up: Dr Ahmad Zaid Zainal (Hospital Kuala Lumpur)
Title: “Analysis of Patients with Poor Ejection Fraction Demonstrated on Nitrates-Enhanced SPECT Rest- Only Imaging and Their Scintigraphy Findings

Basic Science/Translational Research category:

Winner: Dr Wan Amir Nizam (School of Health Sciences, Universiti Sains Malaysia)
Title: “Vascular Endothelium Dysfunction in REM Sleep Deprivation: Prelude to Cardiovascular Disease

1st Runner Up: Dr Tan Jun Jie (Medical and Dental Institute, Universiti Sains Malaysia)
Title: “Induced Pluripotent Stem Cells and its Promises in Cardiovascular Regeneration and Tissue Engineering

2nd Runner Up: Dr Lim Oon Zhi (Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia)
Title: “Combination of Stingless Bee Propolis and Metformin Prevented Diabetic-induced Cardiac Hypertrophy by Reducing Lipid Peroxidation: An Interplay Between AGE and esRAGE in Heart and Plasma

A Unique Model to Accelerate Industry-sponsored Research in Malaysia – Journal for Clinical Studies

This article originally appeared in Volume 11, Issue 1 of the Journal for Clinical Studes.

The influx of industry-sponsored research (ISR) into the Asia Pacific region is continually growing due to the rising costs and complicated processes involved in drug development. Several countries within the region such as Singapore and, more notably, South Korea, have taken the initiative to develop and further strengthen their place as preferred destinations to conduct clinical trials. One such initiative is the establishment of specific entities that focus on nurturing and expanding the existing clinical trial ecosystem within the individual countries. With over 20 years of experience in conducting late-phase trials, the Malaysian government is no exception.

In the last six years, Malaysia has been steadily building a comprehensive and supportive clinical research ecosystem within the country. This includes the creation of Clinical Research Malaysia (CRM), a non-profit company wholly owned by the Ministry of Health (MOH).1 This review will present CRM as a unique business model, established to create a thriving and comprehensive ecosystem for ISRs in Malaysia and how this business model may be relevant and replicated in Asian countries that are looking to focus on attracting ISRs. Read more

Malaysia Collaborates with Two Prominent Singapore Organisations to Advance Clinical Research (VIDEO)

L-R: Dr. Zubaidah Zakariah, Prof. Chng Wee Joo, Dr. Akhmal Yusof, Dato’ Dr. Fadzillah Kamaludin, Datuk Dr. Noor Hisham Abdullah, Datuk Seri Dr. Dzulkefly Ahmad, Mr. Choo Chee Kong, Dato’ Seri Dr. Chen Chaw Min, Dato’ Dr. Goh Pik Pin

KUALA LUMPUR, 26 February 2019 – Clinical Research Malaysia (CRM) inked two Memorandum of Understanding (MoU) with two prominent Singapore organizations in the field of clinical research. This will further pave the way for better Malaysia–Singapore collaborations in advancing drug development and research capabilities between both countries. Read more

Malaysia Pharma Report 2018

Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Tun Dr. Mahathir Mohamad spearheading a bold health policy reform.

Also explored is the emergence of the halal medicine niche – where Malaysia has the potential to be a global leader given its geographic links to Southeast Asia and cultural ties to the Middle East – the first Malaysian biosimilars, the country’s outstanding potential as a regional clinical research hub and the rise of medical tourism.